SWOG clinical trial number
S9623

A Comparison of Intensive Sequential Chemotherapy using Doxorubicin plus Paclitaxel plus Cyclophosphamide with High Dose Chemotherapy and Autologous Hematopoietic Progenitor Cell Support for Primary Breast Cancer in Women with >= 4 Involved Axillary Lymph Nodes, Phase III, Intergroup.

Closed
Phase
Accrual
55%
Published
Abbreviated Title
ADJUVANT: Doxorubicin/paclitaxel/cyclophosphamide vs. High dose chemo and autologous AHPCS
Activated
07/01/1996
Closed
02/15/2001
Participants
NCORP, Members, Medical Oncologists, Radiation Oncologists, Surgeons, Pathologists, ECOG, NCCTG, CALGB

Research committees

Breast Cancer

Treatment

Cisplatin Cyclophosphamide Paclitaxel BCNU Carboplatin Ciprofloxacin hydrochloride Doxorubicin Filgrastim Tamoxifen Thiotepa AC

Eligibility Criteria Expand/Collapse

Hist. doc. breast ca involving >= 4 lymph nodes (at least 10 nodes sampled); no known N3, T4 or M1 dz; mastectomy or breast sparing surgery <= 12 weeks prior to rand.; no prior chemo or hormonal tx; no prior breast RT; no CHF or other significant cardiac dz; no HIV pos.; transplant center participation and approval required; pathology material to be sent for banking; Effective 9/15/00: Southwest Oncology Group institutions must offer ancillary study, S9719.

Publication Information Expand/Collapse

2018

Survival by Hispanic Ethnicity among Cancer Patients Participating in SWOG Clinical Trials

M Chavez-MacGregor;J Unger;A Moseley;S Ramsey;DL Hershman Cancer Apr 15;124(8):1760-1769; Jan 25 [Epub ahead of print]

PMid: PMID29370458 | PMC number: PMC5963502

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

2011

High-dose chemotherapy with autologous stem cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials [PMID21768471]

DA Berry;NT Ueno;MM Johnson;X Lei;J Caputo;S Rodenhuis;W Peters;RC Leonard;WE Barlow;M Tallman;J Bergh;NA Nitz;AM Gianni;RL Basser;A Zander;RC Coombes;H Roche;Y Tokuda;E de Vries;G Hortobagyi;JP Crown;P Pedrazzoli;M Bregni;T Demirer Journal of Clinical Oncology 29(24):3214-3223;

2007

Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623 [PMID17404368]

HCF Moore;SJ Green;JR Gralow;SI Bearman;D Lew;WE Barlow;C Hudis;AC Wolff;JN Ingle;HK Chew;AD Elias;RB Livingston;S Martino Journal of Clinical Oncology 25(13):1677-1682

2005

SWOG/Intergroup 9623: a phase III comparison of intensive sequential chemotherapy to high dose chemotherapy and autologous hematopoietic progenitor cell support (ACHPCS) for primary breast cancer in women with >4 involved axillary lymph nodes.

SI Bearman;SJ Green;J Gralow;W Barlow;C Hudis;A Wolff;J Ingle;G Hortobagyi;R Livingston;S Martino Proc of the ASCO, JCO 23(16S):21s (#572)

Other Clinical Trials

SWOG Clinical Trial Number
S2206

A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
9%
Open
Phase
SWOG Clinical Trial Number
S2212

TIL Adapted Neo adjuvant Chemotherapy Optimization in Triple negative breast cancer (SCARLET)
Research Committee(s)
Breast Cancer
Activated
07/21/2023
Accrual
16%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase